PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
نویسندگان
چکیده
منابع مشابه
Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
The ligation of programmed cell death-1 (PD-1) to its ligands PD-L1 and PD-L2 counteracts T-cell activation, which is critical in immune tolerance. The persistent high expression of PD-1 and PD-L1 are also observed on tumor-infiltrating lymphocytes and various tumor cells, maintaining the highly suppressive microenvironment in tumor sites and promoting tumor malignancies. The blockade of PD-1 a...
متن کاملRegulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Immune checkpoint blockades, such as inhibitors against programmed death 1 (PD-1) and its ligand (PD-L1), have received extensive attention in the past decade because of their dramatic clinical outcomes in advanced malignancies. However, both primary and acquired resistance becomes one of the major obstacles, which greatly limits the long-lasting effects and wide application of PD-1/PD-L1 block...
متن کاملGenetic biomarkers for PD-1/PD-L1 blockade therapy
Immune checkpoint blockade therapy using antibodies against programmed cell death 1 (PD-1) and PD-1 ligand 1 (PD-L1) is revolutionizing cancer treatment (1-3). These antibodies provide long-term durable responses for patients with various types of advanced cancers, such as melanoma, non–small-cell lung cancer, kidney cancer, and Hodgkin lymphoma (1-3). Accumulating evidence suggests that these ...
متن کاملAntitumor Mechanisms of Immune Checkpoints PD-L1/PD-1 Blockade in Cancer Treatment
Programmed death-1 (PD-1) and its ligand (programmed death ligand 1, PD-L1) are negative regulators of immunity. They play a negative role in regulating immune response through interacting with immune cells, resulting in inhibited antitumor response. Tumor immunotherapy with PD-1 or PD-L1 antibody has been shown to be capable of prolonging survival of cancer patients and improving their life qu...
متن کاملPredictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Checkpoint blockades turn on a new paradigm shift in immunotherapy for cancer. Remarkable clinical efficacy, durable response and low toxicity of programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockades have been observed in various malignancies. However, a lot of cancer patients failed to respond to the PD-1/PD-L1 checkpoint blockades. It is crucial to identify a biomar...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biomedicine & Pharmacotherapy
سال: 2019
ISSN: 0753-3322
DOI: 10.1016/j.biopha.2018.11.105